This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of kidney, except renal pelvis신우를 제외한 신장의 악성신생물 (신장암)

A. Classification codes C64 — Malignant neoplasm of kidney, except renal pelvis (mainly renal cell carcinoma; includes Wilms tumor)
B. Synonyms Renal cell carcinoma (RCC), clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), chromophobe renal cell carcinoma (chRCC), Wilms tumor (pediatric), kidney cancer
C. Adult onset Very high — occurs mainly in people in their 50s–70s. Twice as common in men as in women. Incidence is steadily increasing. Wilms tumor is a separate tumor occurring in children (peak at 3–4 years).
Special Copayment Reduction: V193 | 5 years from the date of cancer patient registration | copayment 5%

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

The history of renal cell carcinoma (RCC) begins with the development of pathology in the 19th century. In 1883, Paul Grawitz mistook RCC for a tumor of adrenal origin and named it "hypernephroma," a term that remained in use until the early 20th century. Later pathologic studies confirmed its origin in the proximal tubule, and the current term renal cell carcinoma became established. In 1977, Robson et al. proposed a surgical staging classification for renal malignancies, and radical nephrectomy became established as the standard treatment.

The most important development of the late 20th century was the discovery of the VHL (Von Hippel-Lindau) gene. In 1993, Latif et al. identified the VHL gene on the short arm of chromosome 3 (3p25), and it was established as the key tumor suppressor gene of clear cell RCC. Elucidation of the carcinogenic pathway of VHL gene inactivation → HIF accumulation → VEGF/PDGF overexpression → promotion of angiogenesis became the direct basis for the later development of VEGF-targeted agents (sunitinib, sorafenib, pazopanib). The introduction of sunitinib as first-line therapy for metastatic ccRCC in the 2000s was a paradigm shift in kidney cancer treatment. Subsequently, immune checkpoint inhibitor–TKI combination regimens were established, including nivolumab (PD-1 inhibitor) in 2015, nivolumab + ipilimumab in 2018, and pembrolizumab + axitinib in 2019, and in 2021 the HIF-2α inhibitor belzutifan was approved for VHL disease-associated RCC, opening a new therapeutic area.

2. Causes

The main risk factors for renal cell carcinoma are smoking, obesity, hypertension, and dialysis. Smoking increases RCC risk 1.5–2-fold, and the risk gradually decreases after quitting. Obesity raises RCC risk 1.5-fold in men and more than 2-fold in women, which is presumed to be related to estrogen production in adipose tissue, insulin resistance, and chronic inflammation. Hypertension is also an independent risk factor; an association with the use of some antihypertensives (diuretics) has been raised, but it is difficult to separate from the effect of hypertension itself.

In patients with end-stage renal disease receiving long-term dialysis, the risk of RCC associated with acquired cystic kidney disease is significantly increased. A mechanism in which RCC arises within renal cysts in dialysis patients is involved. VHL syndrome (Von Hippel-Lindau disease) is the most common cause of hereditary RCC; germline variants of the VHL gene lead to clear cell RCC, central nervous system hemangioblastoma, pheochromocytoma, and other tumors. Other hereditary RCC syndromes include hereditary papillary RCC (MET variants), Birt-Hogg-Dubé syndrome (FLCN variants), hereditary leiomyomatosis and RCC (FH variants, type 2 pRCC), and SDH-associated RCC (SDHB/C/D variants). Among occupational exposures, trichloroethylene is associated with ccRCC risk.

3. Genetics

Renal cell carcinomas have distinctly different genetic backgrounds by histologic type. In clear cell RCC (ccRCC, 70–75% of all RCC), VHL gene inactivation is observed in more than 90% (loss, variant, or promoter methylation). Besides VHL loss, epigenetic and mTOR pathway alterations such as PBRM1 (SWI/SNF complex subunit, 40–50%), SETD2 (H3K36 methyltransferase, 10%), KDM5C (histone demethylase, 7%), BAP1 (BRCA1-associated protein, 10–15%), and MTOR (mTOR pathway, 5–8%) are characteristic of ccRCC. BAP1 variants are associated with a poor prognosis.

In papillary RCC (pRCC, 10–15%), the main mechanisms are MET gene variants or amplification in type 1, and FH (fumarate hydratase) variants or NRF2-ARE pathway activation in type 2. Chromophobe RCC (chRCC, 5%) is characterized by TP53, PTEN variants along with loss of multiple chromosomes (1, 2, 6, 10, 13, 17, 21). From a therapeutic target perspective, mTOR inhibitors (everolimus, temsirolimus) are being studied in tumors with mTOR pathway alterations, belzutifan as an HIF-2α-targeted agent in ccRCC, and PARP inhibitors in SDH variant-associated RCC. Pharmacogenomically, sunitinib responsiveness is associated with VEGFR2 polymorphisms, and response to immune checkpoint inhibitors with TMB, MSI, and PD-L1 expression.

4. General epidemiology

Kidney cancer is the 10th most common malignancy worldwide, with about 430,000 new diagnoses in 2020. Incidence is twice as high in men as in women, and it occurs mainly in people in their 50s–70s. Incidence is high in Northern Europe, North America, and Australia and low in Asia and Africa. Over the past 30 years, advances in imaging have increased incidentally detected small renal masses, and incidence is rising worldwide.

In Korea, kidney cancer is steadily increasing, and according to 2021 data from the National Cancer Center, kidney cancer ranks within the top 10 cancers in Korean men. Wide use of abdominal ultrasound and CT is increasing the proportion detected early. In Korea, clear cell renal cell carcinoma is the most common histologic type, followed by papillary and chromophobe types. Hereditary kidney cancers such as VHL syndrome account for 2–3% of the total and mainly occur at a young age as bilateral and multiple tumors.

5. Pathophysiology

The pathogenesis of clear cell RCC is understood around the VHL–HIF–VEGF axis. Normally, the VHL protein hydroxylates proline residues of HIF (hypoxia-inducible factor), degrading it via the ubiquitin–proteasome pathway. When VHL is lost, HIF-1α and HIF-2α are not degraded and accumulate in the nucleus, transcriptionally activating hundreds of hypoxia-responsive genes. Among these, VEGF (vascular endothelial growth factor), PDGF (platelet-derived growth factor), TGF-α, EPO, and GLUT1 are overexpressed, promoting angiogenesis, cell proliferation, and metabolic reprogramming; this explains the rich vascularity of clear cell RCC and its characteristic cytoplasmic lipid and glycogen accumulation (clear appearance).

After VHL loss, additional loss of epigenetic genes such as PBRM1, SETD2, BAP1, and KDM5C contributes to tumor progression and poor prognosis. HIF-2α (EPAS1) is the main oncogenic transcription factor in ccRCC, and belzutifan, which directly inhibits HIF-2α, was approved in 2021. The mTOR pathway (PI3K-AKT-mTOR axis) is also important in ccRCC, and PTEN loss, PIK3CA variants, and mTOR-activating variants intersect with the VHL pathway to promote tumor growth.

6. Symptoms

Today, about 50–60% of kidney cancers are found incidentally on abdominal imaging (ultrasound, CT) performed for other reasons. When symptomatic, the classic Virchow's triad is hematuria, flank pain, and an abdominal mass, but all three symptoms occur together in less than 10%, in advanced lesions.

Hematuria is the most common single symptom, appearing as gross or microscopic hematuria. Flank or abdominal pain occurs when the tumor invades the renal capsule or a thrombus forms. Paraneoplastic syndromes are more common in kidney cancer than in other cancers, and may include erythrocytosis (excess EPO secretion), hypercalcemia (PTHrP secretion), hypertension (renin secretion), nonmetastatic hepatic dysfunction (Stauffer syndrome), and mast cell toxic fever. In advanced lesions, systemic symptoms such as weight loss, fatigue, night sweats, and loss of appetite accompany.

7. Signs

On abdominal examination, an abdominal mass may be palpable when the renal tumor is very large, but small renal masses produce no abnormal findings. If a solid or mixed intrarenal mass is seen on abdominal ultrasound, further workup is performed. In patients with hematuria, red blood cells are confirmed by urinalysis. When a left renal tumor compresses the left renal vein, a left varicocele may develop, which should be recognized as a sign of kidney cancer.

Serum tests may show anemia or erythrocytosis, hypercalcemia, hypertension, abnormal liver function tests, and elevated ESR as biochemical signs of paraneoplastic syndrome. Among imaging findings of renal tumors, strong enhancement on contrast-enhanced CT is characteristic of renal cell carcinoma, reflecting its hypervascularity. Renal vein thrombus and IVC thrombus in advanced lesions are confirmed by CT or MRI.

8. Screening

There is no standard screening program for kidney cancer in the general population, because incidence is low and to date there is no randomized controlled trial evidence that kidney cancer-specific screening reduces mortality. However, in groups at risk of hereditary kidney cancer, such as VHL syndrome, Birt-Hogg-Dubé syndrome, hereditary papillary RCC, and SDH-associated RCC, regular abdominal MRI or ultrasound screening is recommended. In these groups, regular imaging follow-up at 1–2-year intervals starting at an early age (from 20–25 years) is standard.

In long-term dialysis patients with acquired cystic kidney disease (ACDK), the risk of RCC is high, so regular renal ultrasound follow-up is recommended. In addition, when a VHL gene variant carrier is identified, genetic counseling and early testing are offered to at-risk family members. In general, when suspicious symptoms such as abdominal pain, hematuria, or unexplained weight loss are present, immediate abdominal ultrasound and CT are performed to evaluate for a renal tumor.

9. Diagnosis

The key imaging test for diagnosing kidney cancer is abdominal CT (before and after contrast). On contrast-enhanced CT, the presence and pattern of enhancement of a solid renal mass are central to distinguishing malignant from benign. Based on the Hounsfield unit (HU) difference, enhancement of 10 HU or more suggests a high likelihood of malignancy. MRI is useful compared with CT for characterizing small renal masses, evaluating renal vein/IVC thrombus, and in patients who cannot receive contrast. The Bosniak classification system is used to classify the malignancy risk of cystic renal lesions.

For staging, chest CT and bone scan are additionally performed. Brain MRI is performed when brain metastasis is suspected. Percutaneous renal biopsy is performed when preoperative tissue confirmation is needed for the diagnosis of a primary renal tumor (e.g., to differentiate lymphoma, confirm a metastatic lesion, or before systemic therapy in inoperable patients), with an accuracy of more than 95%. The ISUP (International Society of Urological Pathology) nuclear grading system is used for histologic grading. In metastatic ccRCC, PD-L1 expression, TMB, and MSI testing are used to predict response to immune checkpoint inhibitors, but they have limitations as stand-alone predictive markers in ccRCC.

10. Treatment

The standard treatment of localized kidney cancer is surgery. Radical nephrectomy is performed for T2 or higher lesions or those with major vessel invasion, and partial nephrectomy for T1 tumors (≤7 cm) to preserve renal function, with functionally equivalent outcomes. Robot-assisted laparoscopic surgery has become the standard minimally invasive approach. For small renal masses under 4 cm, radiofrequency ablation (RFA), cryoablation, and active surveillance are alternative options.

For first-line treatment of metastatic ccRCC, depending on risk (IMDC criteria), immune checkpoint inhibitor–TKI combination regimens such as nivolumab + ipilimumab (intermediate/poor risk) and pembrolizumab + axitinib, lenvatinib + pembrolizumab (all risk groups) are standard. Belzutifan (HIF-2α inhibitor) has been approved for VHL disease-associated ccRCC and is also used in ccRCC after failure of standard therapy. VEGFR-TKI (sunitinib, pazopanib, cabozantinib, axitinib) monotherapy is used in patients unsuitable for immune checkpoint inhibitors. In non-clear cell RCC (non-ccRCC), MET inhibitors (savolitinib—pRCC) and everolimus (chRCC) are being studied. Adjuvant pembrolizumab (KEYNOTE-564) for high-risk ccRCC after surgery was approved in 2021.

11. Prognosis

The prognosis of kidney cancer is determined by stage and histologic grade.

Stage5-year survival rate (approximate)
Stage I (T1N0M0, ≤7 cm)90–95%
Stage II (T2N0M0, >7 cm)75–85%
Stage III (T3 or N1)50–65%
Stage IV (T4 or M1)Formerly 5%; now improving with combination immunotherapy

In metastatic ccRCC, the 4-year overall survival with nivolumab + ipilimumab combination therapy (CheckMate 214) was reported as about 55% in the intermediate/poor risk groups, a significant improvement over VEGFR-TKI monotherapy. The IMDC prognostic classification (Heng criteria) is used to predict prognosis and select first-line treatment in metastatic RCC. BAP1 variants, high ISUP grade (3–4), and sarcomatoid differentiation are poor prognostic factors.

12. Prevention

The most important lifestyle changes for preventing kidney cancer are smoking cessation, maintaining a healthy weight, and blood pressure control. Smoking raises RCC risk 1.5–2-fold, and the risk gradually decreases after quitting. Obesity management (regular physical activity, a balanced diet, keeping BMI under 25) contributes to RCC prevention. Controlling hypertension with antihypertensives is also important, and adequate fluid intake and a diet centered on vegetables and fruits are recommended.

In groups at risk of hereditary kidney cancer (VHL syndrome, Birt-Hogg-Dubé syndrome, hereditary papillary RCC, SDH-associated RCC, etc.), participation in genetic counseling and early screening programs is central to the prevention strategy. In dialysis patients, kidney transplantation to suppress the long-term development of ACDK is also considered from a prevention perspective. Because occupational trichloroethylene exposure is associated with ccRCC, compliance with workplace exposure standards is important. Protective effects of aspirin, coffee, and whole grains have been suggested in epidemiologic studies, but the evidence is not yet sufficient for clinical recommendations.


13. References

  1. Latif F, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–1320.
  2. Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma (CheckMate 214). N Engl J Med. 2018;378:1277–1290.
  3. Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (KEYNOTE-426). N Engl J Med. 2019;380:1116–1127.
  4. Choueiri TK, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385:2036–2046.
  5. Haake SM, Rathmell WK. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decisions? Cancer. 2017;123(2):200–209.
  6. EAU Guidelines on Renal Cell Carcinoma. 2025.
  7. Korean Urological Association. Clinical practice recommendations for renal cell carcinoma. 2023.
  8. Choueiri TK, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma (KEYNOTE-564). N Engl J Med. 2021;385:683–694.
  9. Srinivasan R, et al. Targeted therapy of VHL-deficient RCC. Nat Rev Urol. 2023;20:199–211.
  10. National Cancer Center. National Cancer Registry Statistics 2021. 2023.